Pfizer (PFE)

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Can Novo Nordisk thrive under intense competitive pressures?

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

Investors can find much better opportunities.

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.

These stocks are facing some headwinds, but they may prove to be big winners in the long run.

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Manag...

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.

It's a great time to "buy low."

The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.

Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launc...

Pfizer's acquired and recently launched products generated strong growth last quarter.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

If you are trying to generate income in retirement, these three high-yield healthcare stocks could be the perfect fit for you.

Look for names that tend to trade independently of the overall market, and don't be afraid to achieve some income growth.